Publications

Publications
  1. Dengxuan Fan, Hailing Yang, Weiqun Mao, Philip J. Rask, Lan Pang, Congjian Xu, Hariprasad Vankayalapati, Ahmed A. Ahmed, , Robert C. Bast, Jr., Zhen Lu. A Novel Salt Inducible Kinase 2 Inhibitor, ARN-3261, Sensitizes Ovarian Cancer Cell Lines and Xenografts to Carboplatin. Cancers (Basel). (2021), 13 (3), 446.
  2. A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel. Zhou J, Alfraidi A, Zhang S, Santiago-O'Farrill JM, Yerramreddy Reddy VK, Alsaadi A, Ahmed AA, Yang H, Liu J, Mao W, Wang Y, Takemori H, Vankayalapati H, Lu Z, Bast RC Jr. Clin Cancer Res. 2017, 23(8), 1945-1954.
  3. SIK2 Restricts Autophagic Flux To Support Triple-Negative Breast Cancer Survival. Maxfield KE, Macion J, Vankayalapati H, Whitehurst AW. Mol Cell Biol. 2016, 36 (24), 3048-3057.
  4. Salt-inducible kinase 2 regulates mitotic progression and transcription in prostate cancer. Bon, H, Wadhwa, K, Schreiner, A, Osborne, M, Carroll, T, Ramos-Montoya, A, Ross-Adams, H, Visser, M, Hoffmann, R, Ahmed, A. A, Neal, D. E, Mills, I. G. Mol Cancer Res, 2015, 13(4), 620-635.
  5. SIK inhibition in human myeloid cells modulates TLR and IL-1R signaling and induces an anti-inflammatory phenotype. Lombardi M. S, Gilliéron, C, Dietrich D2, Gabay, C. J Leukoc Biol, 2015, 99, 1-11.